JADPRO Live 2015 Accredited Educational Activities

Earn CE credit with these accredited educational activities based on presentations from JADPRO Live at APSHO 2015. Access the full-length video presentation, the slide deck, transcript, and the entire lecture as a podcast. You can earn CE for each of these activities by following the links.

Click on any of the video presentations below to get started!

2015

Corner Drug Store

Panel Discussion: Revolution at the Corner Drugstore

There is a rising conflict between innovation and healthcare economics as new oral therapies are incorporated into treatment regimens and health care costs rise. This session presents a candid panel discussion among key stakeholders (e.g. patient advocates, prescribers, and specialty pharmacies) on strategies to confront this looming revolution in an effort to control cost, remove barriers, and improve patient outcomes.

Posted: February 28, 2016 / Expires: February 28, 2017

Credits/Contact Hours: 1.25

Watch Video Without Claiming Credit

Melanoma

Evolving Paradigms in Melanoma Therapy

Learn the science behind immune response and treatment options for Melanoma. This activity provides an overview of differentiating checkpoint inhibitors from options such as kinase inhibitors, and cytotoxic chemotherapy. Discuss potential toxicities, care management, and the AP role in the collaborative practice approach to patient care.

Posted: February 28, 2016 / Expires: February 28, 2017

Credits/Contact Hours: 1.0

Watch Video Without Claiming Credit

Non-Small Cell Lung Cancer

Navigating the Landscape of Molecular Testing and Treatments With Targeted Therapies for Patients With Non-Small Cell Lung Cancer

Keeping current with emerging targeted therapies for NSCLC can be daunting yet exciting. There are multiple options for first, second and even third line treatment, which can effectively delay progression or improve overall survival. This activity provides the AP with a valuable overview and update on NSCLC targeted therapies, molecular testing and recommendations for optimizing patient outcomes with newer emerging treatment options.

Posted: February 28, 2016 / Expires: February 28, 2017

Credits/Contact Hours: 1.0

Watch Video Without Claiming Credit

Chronic Lymphocytic Leukemia

Risk-Stratified Treatment in Chronic Lymphocytic Leukemia

New treatment options and shifting paradigms in the approach and management of CLL patients, present care challenges, especially with newer oral agents. This activity discusses risk-stratification, targeting pathways and best practices to improve patient outcomes: how/when to incorporate old therapies vs. newer treatments and the management of patients with CLL in this rapidly changing treatment landscape.

Posted: February 28, 2016 / Expires: March 28, 2017

Credits/Contact Hours: 1.0

Watch Video Without Claiming Credit

Colorectal

Updates in the Treatment of Metastatic Colorectal Cancer

Ongoing research in the area of metastatic colorectal cancer makes it imperative for the AP to stay informed and knowledgeable about new treatment options. Learn crucial information about current treatment options, mutation testing and the impact on treatment decisions, predictive biomarkers, the role of radiation, and the role of biologics and oral therapies in the management of mCRC.

Posted: February 28, 2016 / Expires: February 28, 2017

Credits/Contact Hours: 1.0

Watch Video Without Claiming Credit

Collaborative Practice in the Management of Patients With Gastrointestinal and Pancreatic Neuroendocrine Tumors

Pancreatic neuroendocrine tumors have unique characteristics and are often unpredictable in their behavior, which necessitates a collaborative approach in diagnosis, treatment, and follow-up. This activity provides valuable information and updates, while highlighting the role of the AP as a vital part of the collaborative team in the overall management of this challenging patient population.

Posted: February 28, 2016 / Expires: February 28, 2017

Credits/Contact Hours: 1.0

Watch Video Without Claiming Credit

Neuroblastoma

Immunotherapy for High-Risk Neuroblastoma

Break through immunotherapy for High-Risk Neuroblastoma presents challenges in administration and symptom management, which requires interprofessional collaboration and family support. This activity will present case studies that clearly define the complexities involved in treatment decisions, symptom management, guidelines for administration, and the role of the collaborative care to improve patient outcomes.

Posted: February 28, 2016 / Expires: February 28, 2017

Credits/Contact Hours: 1.5

Watch Video Without Claiming Credit

Biologics

The Science Behind Biologics and Biosimilars

The introduction of biologics into oncology has been groundbreaking. At a time when many of the “innovator drug” patents expire the new frontier is becoming biosimilars. Unlike established medications, biosimilars and biologics are not chemically synthesized. This activity explains fundamental differences in the complexity of biosimilars, nomenclature, prescribing, documentation and patient education/consent – indispensable information for the oncology AP.

Posted: February 28, 2016 / Expires: February 28, 2017

Credits/Contact Hours: 0.75

Watch Video Without Claiming Credit

Multiple Myeloma

Risk Stratification in Multiple Myeloma

New innovative therapies in MM have increased significantly over the past decade and have improved survival rates. Options now include proteasome inhibitors, immunomodulatory agents, HDAC inhibitors, monoclonal antibodies as well as standard chemotherapy. This activity equips the AP with critical updates in NCCN guidelines, diagnosis, risk-stratification, and treatment options, including: mechanism of action, side effect profile and supportive care.

Posted: February 28, 2016 / Expires: February 28, 2017

Credits/Contact Hours: 1.0

Watch Video Without Claiming Credit

Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer: Immunotherapy

Immunotherapy has made groundbreaking news across tumor types including an exciting emerging role in NSCLC. It is imperative for APs to understand this innovative approach in treating NSCLC. This activity provides an invaluable overview of the immune system, the role of checkpoint inhibitors, unique treatment considerations such as pseudo progression, immune mediated side effect profiles of these newer agents and management.

Posted: February 28, 2016 / Expires: February 28, 2017

Credits/Contact Hours: 0.75

Watch Video Without Claiming Credit

These CME/CE/CPE accredited activities are jointly provided by

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.